Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906788 | 0.92 | LMNA (0.43) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL686152 | 0.85 | HDAC1 (0.39) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL14817461 | 0.84 | HDAC1 (0.45) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL18622527 | 0.83 | LMNA (0.44) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL3093190 | 0.83 | HDAC1 (0.46) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL28255049 | 0.83 | HDAC1 (0.48) | HDAC1HDAC2LMNAEHMT2EHMT1 | |
| SCHEMBL2738376 | 0.82 | LMNA (0.49) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL23336313 | 0.82 | HDAC1 (0.45) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL20272385 | 0.80 | LMNA (0.44) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 | |
| SCHEMBL3099655 | 0.79 | HDAC1 (0.47) | HDAC1HDAC2LMNASMN1; SMN2EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110286935-A1 | Multi-Functional Nano-Device | ATRP Solutions, Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110286935-A1 | Multi-Functional Nano-Device | ATRP Solutions, Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20070276088-A1 | Biomacromolecule Polymer Conjugates | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286935-A1 | Multi-Functional Nano-Device | CD47, FCGRT, FCGR3B | HDAC1 3013/4885HDAC2 3718/4885LMNA 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.